Savicell Diagnostics develops the Well-Shield platform, a blood test designed for the early detection of disease, with a focus on cancer. The Well-Shield technology is designed to detect and interpret differential metabolic responses that can indicate disease intrusion and cell malformation, including cancer. The company aspires to improve adherence to routine medical screenings through the use of patient-friendly blood tests. Savicell Diagnostics is a majority-owned subsidiary of Savicell Corporation, a Nevada-based corporation.